Core Insights - The year 2025 marks a "watershed" moment for China's flow cytometry market, driven by geopolitical uncertainties and a shift towards "deep localization" as a survival necessity for companies [1][2] Market Overview - The total bid amount for flow cytometers in 2025 reached 641,297,934 yuan, with a total of 486 units awarded [3] - BD retained the top position in bid amounts, while Beckman Coulter surpassed BD in bid quantity, indicating a significant market reshuffle influenced by geopolitical factors and localization strategies [2][5] Competitive Landscape - Beckman Coulter emerged as the top bidder in terms of quantity, while BD maintained the highest bid amount, with the gap in bid amounts between the two companies narrowing from nearly 20% in 2024 to less than 3% in 2025 [10] - The top three companies accounted for over 60% of the total bid amount, while the top ten accounted for over 90% [3][5] Product Performance - Beckman Coulter dominated the top ten bid models, securing the first, second, fifth, and sixth positions with models such as DxFLEX and CytoFLEX [7][9] - The highest bid price for a flow cytometer was 11,486,000 yuan for Standard BioTool's Hyperion XTi, while the lowest was under 50,000 yuan for a model from Rescale [11] User Demand and Market Trends - Hospitals accounted for approximately 48.83% of the bid amount and 48.03% of the bid quantity, with a notable increase in demand from disease control centers, particularly due to a large order from the Xinjiang CDC [15] - The market is witnessing a shift towards lower-tier cities, with significant growth expected in the southwest and central regions of China [20] Regional Insights - The top regions for flow cytometer bids in 2025 included Guangdong (11.9%), Beijing (10.8%), and Shanghai (9.9%), with increasing demand in the southwest and central regions [17][19]